Literature DB >> 7563513

Maintaining low HIV seroprevalence in populations of injecting drug users.

D C Des Jarlais1, H Hagan, S R Friedman, P Friedmann, D Goldberg, M Frischer, S Green, K Tunving, B Ljungberg, A Wodak.   

Abstract

OBJECTIVES: To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (< 5%) during at least 5 years. DESIGN AND
SETTING: A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario. Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. PARTICIPANTS: Injecting drug users recruited from both drug treatment and non-treatment settings in each city.
INTERVENTIONS: A variety of HIV prevention activities for IDUs had been implemented in each of the five cities.
RESULTS: There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs. Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections.
CONCLUSIONS: In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.

Entities:  

Mesh:

Year:  1995        PMID: 7563513     DOI: 10.1001/jama.274.15.1226

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  57 in total

Review 1.  Global impact of human immunodeficiency virus and AIDS.

Authors:  H D Gayle; G L Hill
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?

Authors:  V D Hope; A Judd; M Hickman; T Lamagni; G Hunter; G V Stimson; S Jones; L Donovan; J V Parry; O N Gill
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?

Authors:  E Wood; M W Tyndall; P M Spittal; K Li; T Kerr; R S Hogg; J S Montaner; M V O'Shaughnessy; M T Schechter
Journal:  CMAJ       Date:  2001-08-21       Impact factor: 8.262

4.  Ignoring 'downstream infection' in the evaluation of harm reduction interventions for injection drug users.

Authors:  H A Pollack
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

5.  Characteristics and utilization patterns of needle-exchange attendees in Chicago: 1994-1998.

Authors:  H Brahmbhatt; D Bigg; S A Strathdee
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

6.  The Changing Epidemic of HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

7.  Explaining the geographical variation of HIV among injection drug users in the United States.

Authors:  D Ciccarone; P Bourgois
Journal:  Subst Use Misuse       Date:  2003-12       Impact factor: 2.164

8.  Public funding of US syringe exchange programs.

Authors:  Don C Des Jarlais; Courtney McKnight; Judith Milliken
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

9.  Mental health case management as a locus for HIV prevention: results from case-manager focus groups.

Authors:  John A Encandela; Wynne S Korr; Kathleen Hulton; Gary F Koeske; W Dean Klinkenberg; Laura L Otto-Salaj; Anthony J Silvestre; Eric R Wright
Journal:  J Behav Health Serv Res       Date:  2003 Oct-Dec       Impact factor: 1.505

Review 10.  Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done.

Authors:  D C Des Jarlais; S R Friedman
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.